Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Latest Information Update: 26 Apr 2024
At a glance
- Drugs VTI-001 (Primary) ; Carbachol
- Indications Presbyopia
- Focus Registrational; Therapeutic Use
- Acronyms BRIO-II
- Sponsors Visus Therapeutics
- 22 Apr 2024 Planned End Date changed from 31 May 2023 to 31 Dec 2024.
- 22 Apr 2024 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2024.
- 02 Mar 2023 According to a Visus Therapeutics media release, topline data is expected in 1H 2023.